[Peginterferon alfa-2b and ribavirin-induced pure red cell aplasia during treatment of chronic hepatitis C treated by cyclosporin A with good response].
Kato
Motoyasu
M
Department of Internal Medicine, Social Insurance Chuo General Hospital, Tokyo.
Ryu
Tomiko
T
Miura
Hideaki
H
Yamada
Haruki
H
Saito
Tosikazu
T
D000280:Administration, Inhalation; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016572:Cyclosporine / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000188:drug therapy*; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D016572:Cyclosporine; C417083:peginterferon alfa-2b